Company Profile
IBA Proton Therapy Inc. -North America
Company Overview
Particle Therapy: the next frontier in cancer therapy. IBA is the undisputed leader in particle therapy, acknowledged to be the most precise and effective clinical radiotherapy method in the selective destruction of cancer cells. To date, more than 62 world renowned medical institutions have built a Particle Therapy Center with IBA.
IBA: opening new ways in the fight against cancer. IBA is a cancer diagnostics and Treatment Company and the worldwide technology leader in the field of proton therapy. The Company’s expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA’s leading fully integrated IntegraLab® Radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.
Internationally Headquartered in Belgium, with a North America Headquarters in Washington D.C Metro area; IBA currently employs more than 1,300 people worldwide. IBA currently has installed systems across Europe and the US and is expanding into emerging markets.
Company History
IBA History
1986
Founded by Yves Jongen in 1986, IBA is as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), Belgium. Initially active in medical imaging, the company turned its attention to radiotherapy and developed cyclotrons and integrated proton therapy centers which are able to treat numerous forms of cancer with a degree of precision and efficacy never reached before.
1992
In 1992, IBA expands activities into the industrial sector of sterilization and ionization by introducing the Rhodotron®, a new type of particle accelerator producing an electron beam based on a patented concept of the French Atomic Energy Commission.
1997
IBA employees got together in 1997 in an employee buyout of the shares of the company. The purpose was to raise their involvement in, and reward their commitment to, the success of the company while also giving themselves the opportunity to drive its future.
1998
In 1998 IBA introduces a cyclotron revolutionizing the world of proton therapy. The IBA isochronous cyclotron-based solution is today the simplest and most effective way to produce 230 MeV protons and will be used in more than 20 Proton therapy centers all over the world.
1998
In June 1998, funds are raised on the Brussels stock market from an initial public offering to enable IBA to accelerate development through internal growth and acquisitions.
1998/1999
IBA enters the field of dosimetry through the acquisition of Scanditronix and Wellhöfer. The new entity called IBA Dosimetry represents the most important player worldwide in the dosimetry market and reinforces IBA's presence in the medical world.
1999
IBA consolidates its strength in irradiation technologies with the acquisition of Radiation Dynamics, Inc. in February 1999. RDI was well established in the field of high-power low-energy E-beam accelerators used for heat shrinking and polymer modification applications.
2001
Acquisition of Eastern Isotopes. In 2001, IBA becomes the majority shareholder of Eastern Isotopes, Inc., founded in 1993 in Sterling, Virginia, USA. Eastern Isotopes produces standard nuclear medicine products, while expanding into new PET imaging products, most notably FDG. The acquisition allows IBA to leverage its global expertise and innovation, and to offer its customers an international distribution network, more research isotopes and greater access to advanced cyclotron technology.
2001
In 2001, the first patient is treated with a PT system installed by IBA at the Massachusetts General Hospital in Boston (now known as the Francis H. Burr Proton Therapy Center). Since then, through relentless effort and commitment, IBA has installed over half of the clinically driven PT centers worldwide and has become the undisputed leader in the field.
2004
In 2004, the Indiana University Health Proton Therapy Center in Bloomington, Indiana (USA) treats its first patient using protons. A few months later, the Wanjie Proton Therapy Center in Zibo, China, starts treating patients with protons.
2006
On April 20th 2006, IBA reveals its new corporate identity expressing its focus on the fight against cancer and its mission to Protect, Enhance and Save Lives. The different companies acquired throughout the years and IBA core activities are integrated in business units to form today’s worldwide group.
2006-2008
IBA activities for the production and distribution of radiopharmaceuticals are developed in Europe through the acquisition of the Schering radiopharmaceutical business and CIS bio International, making IBA the largest European PET radio-isotopes network. As a second step, in 2008, IBA fully acquires the CISBIO organization with a complete line of SPECT radiopharmaceuticals and additional FDG production facilities. The acquisition of CISBIO makes the company one of the world's largest players in the radiopharmaceutical business.
2007
In June 2007, IBA opens a new facility in Beijing, China, giving the company Asian Headquarters to support all its business units in Asia. This move is part of an overall development program to optimize opportunities in one of the world’s fastest growing markets.
2008
In 2008, the highly precise treatment mode “Pencil Beam Scanning”, developed in collaboration with Massachusetts General Hospital (MGH), is approved by the U.S. Food and Drug administration. A few months later, physicians at MGH’s Francis H. Burr Proton Therapy Center use Pencil Beam Scanning to treat patients.
2008
Acquisition of CISBIO's drug discovery activities. For more than 25 years, CISBIO Bioassays, now a member of the IBA Group, has explored biology and immunoassay design to provide physicians, biologists, clinical chemists and scientists with enhanced solutions for improving patient care. CISBIO Bioassays dedicates its expertise to delivering cutting-edge assays and services to clinical medicine and pharmaceutical research.
2009
In 2009, IBA’s proton therapy activity continues to grow with more successful developments in the field. The four beam modes of IBA’s Universal Nozzle, an all-in-one integrated system to treat patients, are utilized by physicians. Physicians at ProCure Treatment Center in Oklahoma City, Oklahoma (USA) use the new Inclined-beam Treatment Room and deploy the new Empath® 360°gantry room to treat patients.
2012
IBA creates a strategic alliance with SK Capital Partners to create IBA Molecular Imaging, a jointly-owned company derived from IBA’s Molecular Imaging division. SK Capital Partners owns 60% of the company while IBA has a 40% stake.
May 2012
Olivier Legrain becomes Chief Executive Officer replacing Pierre Mottet. Olivier Legrain joined the company in 1996 as Financial Controller. He further pursued his career in the company as President of the IBA Dosimetry business line from 1999 to 2003. From 2003 till 2010 he became President of the IBA Molecular business line. Thereafter he took over the role of Chief Strategy Officer of the Group.
2013
Yves Jongen, Founder and Chief Research Officer of IBA, is nominated for the European Inventor of the Year Award from the European Patent Office for his lifetime contribution to developing new solutions in proton therapy and making this next generation targeted cancer treatment more accessible to cancer patients worldwide.
2013
Following its strategy to focus on its proton therapy, accelerators and dosimetry activities, IBA sells Cisbio Bioassays, to Argos Soditic. Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery.
2014
First patient treated with IBA’s compact proton therapy solution: Proteus®ONE. The Willis-Knighton Cancer Center in Louisiana has treated its first patient with the IBA’s compact solution, Proteus®ONE.
Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, and easier to install and to operate.
2014
IBA and Philips united for cancer treatment. Philips and IBA are united to make cancer diagnostic and treatment technology progress. The collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. The collaboration will also enable both organizations to mutually leverage technologies and solutions: IBA will benefit from Philips’ diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA proton therapy solutions within its offering to customers in select markets around the world.
2014
FDA’s Marketing Authorization for CBCT technology. IBA is the first company to receive the Marketing Authorization from the FDA for the Proton Therapy specific Cone Beam Computed Tomography (CBCT) technology. IBA has received combined clearances from the U.S Food and Drug Administration, that enable the CBCT solution to be marketed in IBA’s two Proton Therapy solutions Proteus®PLUS and Proteus®ONE. As a component of IBA’s Image Guided Proton Therapy (IGPT) solution, CBCT provides 3D imaging for increased accuracy in patient treatment.
2016
IBA S.A. completes sale of IBA Molecular. Following its strategy to focus on its historical trade, namely proton therapy and its associated technology, IBA has finalized the sale of IBA Molecular (“IBAM”) in which IBA had a 40% stake, to funds advised by CapVest Partners LP (“CapVest”).
2016
First patient treated with the Proteus®ONE solution in Europe. The first patient treated with the Proteus®ONE solution in Europe is at the center Antoine Lacassagne in France. The treatment of this first patient with the Proteus®ONE solution in Europe is another important milestone for IBA’s unique superconducting accelerator.
Notable Clients
UPenn Peralman Cancer Center, Procure, ProNova,
Notable Accomplishments / Recognition
We've treated over 50,000 Cancer patients using Proton Therapy in 21 countries worldwide
Benefits
Relocation Assistance
Car Allowances - depending the role
International Travel
Tuition Assistance